Alexandra Sanchez
Cardiovascular Disease · New Orleans, LANPI 1073041174
Payments from drug & device makers
What this record shows
The money is spread across several categories — grants (59.7%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 27 manufacturers reported payments, led by Abbott at 45.9% of the total. Reporting peaked in 2023 at $28,010 and has fallen 67.0% since, to $9,247 in 2025. Among cardiovascular disease clinicians in LA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 380 payments — averaging $181.73 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$32K
- Medtronic$20K
- Biotronik Inc.$6K
- Boston Scientific$5K
- Philips North America LLC$1K
- Amgen$1K
- plus $5K from 21 others
What the payments were for
- Grants$41,25060%
- Travel & lodging$11,35116%
- Food & beverage$15,74523%
- Education$7101%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 63 | $31,714 |
| Medtronic | 68 | $19,765 |
| Biotronik Inc. | 31 | $5,552 |
| Boston Scientific | 24 | $4,839 |
| Philips North America LLC | 7 | $1,130 |
| Amgen | 30 | $1,041 |
| AstraZeneca | 34 | $720 |
| Novo Nordisk | 9 | $710 |
| Pfizer | 29 | $523 |
| E.r. Squibb & Sons, L.L.C. | 30 | $473 |
| Biosense Webster, Inc. | 7 | $449 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 7 | $446 |
| Astellas Pharma US Inc | 5 | $252 |
| Boehringer Ingelheim | 4 | $195 |
| BD | 1 | $191 |
| Alnylam Pharmaceuticals Inc. | 3 | $169 |
| Inari Medical, Inc. | 2 | $146 |
| Kestra Medical Technology Services, Inc. | 6 | $139 |
| Lantheus Medical Imaging, Inc. | 2 | $137 |
| Edwards Lifesciences | 1 | $125 |
| Esperion Therapeutics, Inc. | 7 | $112 |
| Johnson & Johnson | 4 | $67 |
| Shockwave Medical, Inc | 1 | $43 |
| Cardiva Medical, Inc. | 2 | $42 |
| Lexicon Pharmaceuticals, Inc. | 1 | $28 |
| Merck | 1 | $25 |
| Livanova USA, Inc. | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Solia$2,097
- BioMonitor$2,097
- Micra$1,843
- ENSITE PRECISION$1,723
- Acticor$1,595
- Edora$1,595
- Rivacor$1,595
- WATCHMAN Access System$1,536
- S-ICD System Magnet$1,012
- ENSITE$910
- Acticor 7 VR-T DX$833
- Edora 8 DR-T$725
- Rivacor 7 DR-T$725
- Repatha$557
- (9124) LM Undivided$493
- (9520) IGT Devices Undivided$452
- GALLANT$438
- AURORA EV-ICD MRI SURESCAN$292
- COREVALVE EVOLUT R$275
- FLOWTRIEVER CATHETER, S$260
How this compares
$69,056 in reported general payments places this provider in the 95th percentile of 281 cardiovascular disease providers in Louisiana.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 36 | $31,824 |
| Sucralfate | 30 | $854 |
| Flecainide Acetate | 35 | $703 |
| Verapamil SrVerapamil Hcl | 19 | $685 |
| Metoprolol Succinate | 34 | $603 |
| Amiodarone Hcl | 49 | $544 |
| Doxycycline Hyclate | 89 | $366 |
| Pantoprazole Sodium | 61 | $275 |
| ClopidogrelClopidogrel Bisulfate | 15 | $136 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $523 | $31,82436 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 281 cardiovascular disease providers in Louisiana.
Other cardiovascular disease in New Orleans
- Keith FerdinandNew Orleans$239K
- Carl LavieNew Orleans$228K
- Nabeel SaghirNew Orleans$49K
- Aimee HiltboldNew Orleans$29K
- Richard MilaniNew Orleans$28K
- Salima QamruddinNew Orleans$27K
- Joseph EnglertNew Orleans$19K
- Emmett ChapitalNew Orleans$13K
- Yvonne GillilandNew Orleans$13K
- Frank WilklowNew Orleans$12K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.